This proposal will create a center for Large Scale Production of Perturbagen-lnduced Cellular Signatures at Harvard Medical School and collaborating institutions, with a focus on perturbations provoked by small molecule drugs and cellular signatures measured using diverse biochemical and single-cell assays. The result will be a large, self-consistent and diverse set of network-centric Pharmacological Response Signatures that provide unique insight into disease processes, drug mechanism/selectivity and ultimately patient-specific responses to therapy. The initial focus of the Center will be small molecule kinase inhibitors, versatile perturbagens with high translational potential. We will use known inhibitors and also expand dramatically the publicly documented collection of inhibitors through new medicinal chemistry and use of kinome-wide selectivity assays. The responses of a large collection of human tumor cells and some primary cells to kinase inhibitors, will be assayed using multiplex biochemical assays (for 20-100 proteins) involving bead-based sandwich immunoassays and reverse-phase lysate microarrays, and single-cell assays (using imaging and flow cytometry) for cell cycle state, commitment to senescence or apoptosis, mesenchymal vs. epithelial phenotype and markers of primitive (stem-cell) status. Data will be collected, integrated and distributed using a series of novel, interoperable software tools that manipulate semantically-typed data arrays based on a new XML/HDF5 format. A multi-faceted informatics program will link these phenotypic and biochemical measures of cellular response to a rich and growing set of genomic data being collected by others. These goals will be met through pursuit of six linked specific aims.
Aim 1 will focus on existing - largely clinical grade - kinase inhibitors and a set of 45 cell lines that are known to display diverse drug responses and for which extensive genomic data are available.
Aim 2 will enlarge the set of perturbagens by developing a large library of kinase inhibitors using new and existing chemistry and profiling biochemical specificity across the kinome.
Aim 3 will combine existing and novel compounds in a dose-response analysis across a set of >1000 tumor cell lines to identify representative cell lines and outliers which, in Aim 4, will subjected to detailed analysis at a single-cell level.
Aims 5 -6 will develop and deploy the information processing systems needed to collect, systematize and distribute diverse data types. This will involve a novel set of interoperable software tools that incorporate emerging no-SQL and semantic web concepts. Methods for adaptive experimental design will be developed to focus data collection on those areas of the dose response landscape where signatures are most informative. The final product will be a large publicly available data set radically different from, but highly complementary to, the expression profiles and genome data that are the primary focus of current high-throughput biological studies on perturbagen-induced cellular signatures.

Public Health Relevance

Plans for an HMS-based LINCS Center are directly relevant to programmatic goals of assembling mechanism-based associations among the effects of disparate biological perturbations and insight into the mechanisms of action of known drugs. Single -cell and biochemical data generated by the HMS LINCS Center will be different from and complementary to existing large scale data based on genomic assays and transcriptional profiles. The Center's focus on clinical-grade and novel kinase inhibitors will provide data with high translational potential for a class of compounds that currently dominates investigational new drugs for cancer.

Agency
National Institute of Health (NIH)
Institute
National Human Genome Research Institute (NHGRI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HG006097-03
Application #
8332363
Study Section
Special Emphasis Panel (ZRG1-CB-P (52))
Program Officer
Ajay, Ajay
Project Start
2010-09-27
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$2,507,018
Indirect Cost
$675,571
Name
Harvard University
Department
Anatomy/Cell Biology
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Adler, Melanie; Ramm, Susanne; Hafner, Marc et al. (2016) A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol 27:1015-28
Lee, John K; Phillips, John W; Smith, Bryan A et al. (2016) N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell 29:536-47
Sokolov, Artem; Paull, Evan O; Stuart, Joshua M (2016) ONE-CLASS DETECTION OF CELL STATES IN TUMOR SUBTYPES. Pac Symp Biocomput 21:405-16
Sokolov, Artem; Carlin, Daniel E; Paull, Evan O et al. (2016) Pathway-Based Genomics Prediction using Generalized Elastic Net. PLoS Comput Biol 12:e1004790
Drake, Justin M; Paull, Evan O; Graham, Nicholas A et al. (2016) Phosphoproteome Integration Reveals Patient-Specific Networks in Prostate Cancer. Cell 166:1041-54
Lee, Sebum; Shang, Yulei; Redmond, Stephanie A et al. (2016) Activation of HIPK2 Promotes ER Stress-Mediated Neurodegeneration in Amyotrophic Lateral Sclerosis. Neuron 91:41-55
Fallahi-Sichani, Mohammad; Moerke, Nathan J; Niepel, Mario et al. (2015) Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol Syst Biol 11:797
Faber, Anthony C; Farago, Anna F; Costa, Carlotta et al. (2015) Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A 112:E1288-96
Tan, Li; Nomanbhoy, Tyzoon; Gurbani, Deepak et al. (2015) Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Med Chem 58:183-96
Van Rechem, Capucine; Black, Joshua C; Greninger, Patricia et al. (2015) A coding single-nucleotide polymorphism in lysine demethylase KDM4A associates with increased sensitivity to mTOR inhibitors. Cancer Discov 5:245-54

Showing the most recent 10 out of 64 publications